Biomarkers of Therapeutic Response in the IL-23 Pathway in Inflammatory Bowel Disease-Reference-Cited by-同舟云学术

Biomarkers of Therapeutic Response in the IL-23 Pathway in Inflammatory Bowel Disease

Published:2012-02 Issue:2 Volume:3 Page:e10
ISSN:2155-384X
Container-title:Clinical and Translational Gastroenterology
language:en
Short-container-title:

Author:

Cayatte Corinne,Joyce-Shaikh Barbara,Vega Felix,Boniface Katia,Grein Jeffrey,Murphy Erin,Blumenschein Wendy M,Chen Smiley,Malinao Maria-Christina,Basham Beth,Pierce Robert H,Bowman Edward P,McKenzie Brent S,Elson Charles O,Faubion William A,de Waal Malefyt Rene,Kastelein Robert A,Cua Daniel,McClanahan Terrill K,Beaumont Maribel

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Gastroenterology

Link

http://www.nature.com/articles/ctg20122.pdf

Reference46 articles.

1. The Interleukin-23 / Interleukin-17 axis in intestinal inflammation

2. Novel p19 Protein Engages IL-12p40 to Form a Cytokine, IL-23, with Biological Activities Similar as Well as Distinct from IL-12

3. A Receptor for the Heterodimeric Cytokine IL-23 Is Composed of IL-12Rβ1 and a Novel Cytokine Receptor Subunit, IL-23R

4. IL-23 is essential for T cell–mediated colitis and promotes inflammation via IL-17 and IL-6

5. Anti-IL-23 therapy inhibits multiple inflammatory pathways and ameliorates autoimmune encephalomyelitis

Cited by 48 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Identification of the grass carp interleukin-23 receptor and its proinflammatory role in intestinal inflammation;International Journal of Biological Macromolecules;2024-04

2. High-throughput omics technologies in inflammatory bowel disease;Clinica Chimica Acta;2024-03

3. Emerging drugs for the treatment of moderately to severely active ulcerative colitis: review of phase II and III clinical trials;Expert Opinion on Emerging Drugs;2023-01-02

4. DMBT1 Alleviates Nasal Airway Inflammatory Response in the LPS-Induced Nasal Polyp Model;International Archives of Allergy and Immunology;2023

5. circSMAD4 Promotes Experimental Colitis and Impairs Intestinal Barrier Functions by Targeting Janus Kinase 2 Through Sponging miR-135a-5p;Journal of Crohn's and Colitis;2022-10-14